Send us a text

Continuamos con el mes de hepatología. ¡No olviden suscribirse para el próximo episodio!

Bibliografía:
Buckman, R. A. (2005). Breaking bad news: the SPIKES strategy. Community oncology, 2(2), 138-142.

Kamath, P. S., & Kim, W. R. (2007). The model for end‐stage liver disease (MELD). Hepatology, 45(3), 797-805.

Wong, F., Pappas, S. C., Curry, M. P., Reddy, K. R., Rubin, R. A., Porayko, M. K., ... & Jamil, K. (2021). Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. New England Journal of Medicine, 384(9), 818-828.

Wong, F., Pappas, S. C., Reddy, K. R., Vargas, H. E., Curry, M., Jamil, K., & Sanyal, A. (2021). Increased incidence of respiratory failure with terlipressin use in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. J Hepatol, 75, S326.

Instragram: @MADE.podcast.MD
[email protected]
Tik Tok: MD. Medical Spanish